Abstract 3953: Ex-Vivo Nanofiber Expansion and Genetic Modification of Human Cord Blood-Derived Stem Cells Enhances Vasculogenesis
The stem cells therapy for treating ischemic diseases is promising; however, the limited availability and compromised quality of progenitor cells in aged and diseased patients limit its therapeutic use. Here we report a nanofiber based ex-vivo stem cell expansion technology and proangiogenic growth factors transfection of the human umbilical cord blood (UCB)-derived progenitor cells to enhance angiogenic potential of therapeutic stem cell. The human UCB-derived progenitor cells were expanded ~225 fold on nanofiber based serum free ex vivo expansion culture technique. This nanofiber ex vivo expansion technique did not induce stem cell differentiation in culture, and retained their stem cell ness. The expanded cells express high levels of stem cell homing receptor, CXCR4 and adhesion molecule, LFA-1. The nanofiber expanded stem cells uptake AcLDL effectively, and migrate efficiently in an in vitro transmigration assay. To demonstrate their bipotential differentiation ability, these expanded cells can also differentiate into endothelial and smooth muscle cells in vitro. In a NOD/SCID mouse hind limb vascular injury model, nanofiber-expanded cells were more effective in blood flow restoration and neovascularization, and these effects were further augmented by VEGF164 and PDGF-BB, growth factors overexpression on nanofiber-expanded stem cells. Nanofiber based ex-vivo expansion technology provides a way to increase the number of available therapeutic stem cells. Additionally, proangiogenic growth factors transfection can potentially improve autologous or allogeneic stem cell therapy for ischemic diseases.